Studies correlating neoadjuvant chemotherapy response with survival across early breast cancer subtypes, especially in aggressive types like triple-negative breast cancer (TNBC) and Her2-positive cancers, have highlighted the importance of achieving a pathological complete response (pCR) [2]. This evidence concerns the gene ERBB2 and cancer.